145 related articles for article (PubMed ID: 37375297)
21. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
22. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
23. Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells.
Ota A; Kawai M; Kudo Y; Segawa J; Hoshi M; Kawano S; Yoshino Y; Ichihara K; Shiota M; Fujimoto N; Matsunaga T; Endo S; Ikari A
Arch Biochem Biophys; 2023 Feb; 735():109519. PubMed ID: 36642262
[TBL] [Abstract][Full Text] [Related]
24. Identification of the gossypol derivatives as androgen receptor inhibitor.
Zhang R; Wu M; Cao T; Luo K; Huang F; Zhang R; Huang Z; Zhou J; Wang Y; Zhu S
Bioorg Med Chem Lett; 2022 Nov; 75():128952. PubMed ID: 36031018
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer.
Zhang S; Meng X; Zhang S; Li B; Jin W; Zhang C; Liu Z; Hu X; Ge L; Yu Z; Li Z; Ma S; Wang X; Li L; Qin C
J Med Chem; 2023 Apr; 66(7):4784-4801. PubMed ID: 36960664
[TBL] [Abstract][Full Text] [Related]
26. Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.
Dong J; Wu Z; Wang D; Pascal LE; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2019 Jan; 18(1):39-50. PubMed ID: 30297360
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
29. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
30. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
Isharwal S; Modi S; Arora N; Uhlrich C; Giri B; Barlass U; Soubra A; Chugh R; Dehm SM; Dudeja V; Saluja A; Banerjee S; Konety B
Prostate; 2017 May; 77(6):584-596. PubMed ID: 28144973
[TBL] [Abstract][Full Text] [Related]
31. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
32. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
33.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
34. Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting.
Sawant M; Mahajan K; Renganathan A; Weimholt C; Luo J; Kukshal V; Jez JM; Jeon MS; Zhang B; Li T; Fang B; Luo Y; Lawrence NJ; Lawrence HR; Feng FY; Mahajan NP
Sci Transl Med; 2022 Jun; 14(649):eabg4132. PubMed ID: 35704598
[TBL] [Abstract][Full Text] [Related]
35. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
36. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
37. Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.
Yu J; Zhou P; Du W; Xu R; Yan G; Deng Y; Li X; Chen Y
Biochem Pharmacol; 2020 Jul; 177():113946. PubMed ID: 32247852
[TBL] [Abstract][Full Text] [Related]
38. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
39. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
Yu Z; Cai C; Gao S; Simon NI; Shen HC; Balk SP
Clin Cancer Res; 2014 Aug; 20(15):4075-85. PubMed ID: 24874833
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
